FDA News: FDA approves first treatment for episodic cluster headache that reduces the frequency of attacks

FDA News: FDA approves first treatment for episodic cluster headache that reduces the frequency of attacks

Silver Spring, MD (STL.News) – The U.S. Food and Drug Administration today approved Emgality (galcanezumab-gnlm) solution for injection for the treatment of episodic cluster headache in adults.

“Emgality provides patients with the first FDA-approved drug that reduces the frequency of attacks of episodic cluster headache, an extremely painful and often debilitating condition,” said Eric Bastings, M.D., deputy director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research.

Continue reading FDA News: FDA approves first treatment for episodic cluster headache that reduces the frequency of attacks at STL.News.